Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial
Laquinimod for Relapsing-Remitting Multiple Sclerosis
Is Teva doomed after Copaxone's increased competition and Laquinimod's failed Phase III trial? - Pharmaceutical Technology
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study - The Lancet
Insight into the mechanism of laquinimod action - Journal of the Neurological Sciences
Teva launches personalised digital support for MS patients - PMLiVE
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Website: www.tevapharm.com www.activebiotech.com ORAL LAQUINIMOD DEMONSTRATED SUSTAINED EFFICACY AND SAFETY IN PATIENTS WITH M
Teva and Active Biotech Expand Investigational MS Treatment Program
Laquinimod - Wikipedia
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Multiple Sclerosis Research: Will Teva and Biogen Come together for the sake of DMF, laquinimod polypill
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Laquinimod - an overview | ScienceDirect Topics
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
Laquinimod - Wikipedia
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women | Request PDF
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Teva's Respiratory Drugs Contribute 11% to Specialty Medicines
Teva gets patent for invention related to multiple sclerosis drug | Business Standard News
Laquinimod | ≥99%(HPLC) | Selleck | Immunology & Inflammation related modulator
